Abstract 210P
Background
Vascularization is known to be linked to tumour growth. We explored the potential of automated lung tumour vascularity assessment as risk factor for landmark survival.
Methods
131 CT scans from the NSCLC Radiogenomics dataset were evaluated. All patients underwent surgery, with or without other therapies. Primary lung tumour (PLT) is segmented by a radiologist. Vessels segmentation (arteries and veins) is performed by an in-house deep learning segmentation model. Vascularity features extracted for the PLT include: amount of blood vessel connections, % of the tumour surface connected to vessels (%area), and basic statistics on the surface area of the connections. A generalized linear model (GLM) to predict landmark survival was trained with these features, tumour volume, and clinical factors. Stepwise feature reduction was performed to arrive to the final model. We present the odds ratio (OR) as well as a combined risk score for the remaining independent predictors.
Results
Landmark survival was reached for 86/131 (66%) patients. GLM analysis showed 4 independent risk factors related to landmark survival: %area (OR= 1.69 for >2.5%), age (OR=1.57 for >70 years), gender (OR=2.10 for male) and radiation therapy (OR=1.51 for yes). Smoking status and tumor volume were not retained in the final model. We also showed that risk of dying before landmark survival increased with increased number risk factors (0%, 18%, 40%, 48% and 100% for 0, 1, 2, 3, 4 risk factors, respectively).
Conclusions
Lung tumour vascularity is an independent risk factor for landmark survival. We showed an approach were it can be used as additional prognostic factor to inform clinical decision making and therapy planning.
Clinical trial identification
Editorial acknowledgement
Fabio Bottari, PhD, of Radiomics for providing medical writing support in accordance with Good Publication Practice ( GPP 2022) guidelines.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Blistein, F. Belmans, S. Goffart, L. Libert, R. Narasimhan, A. Corsi: Financial Interests, Personal, Full or part-time Employment: Radiomics. W. Vos: Financial Interests, Personal, Leadership Role: Radiomics. M. Occhipinti: Financial Interests, Personal, Financially compensated role: Radiomics. All other authors have declared no conflicts of interest.
Resources from the same session
206P - WAYFIND-R: A global, real-world database of patients (pts) with a solid tumour profiled with next-generation sequencing (NGS)
Presenter: Jean-Yves Blay
Session: Poster session 01
207P - Palbociclib (P) in patients (pts) with solid tumors with CDK4 or CDK6 amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Presenter: Maged Khalil
Session: Poster session 01
208P - Identification of BCOR mutation as a novel predictor of immunotherapy efficacy in gastrointestinal tumors
Presenter: Wuping Wang
Session: Poster session 01
209P - Molecular atlas of copy number variation(CNV) in lung cancer with brain metastases
Presenter: Xianfeng Zhang
Session: Poster session 01
211P - Cost-efficient detection of NTRK1, NTRK2 and NTRK3 gene rearrangements using the test for 5’/3’-end unbalanced expression: The analysis of 8075 patients
Presenter: Evgeny Imyanitov
Session: Poster session 01
212P - Extracellular vesicle miRNA as effective biomarkers for predicting antitumor efficacy in lung adenocarcinoma treated with chemotherapy and checkpoint blockade
Presenter: Si Sun
Session: Poster session 01
213P - Unlocking cancer treatment opportunities by population-based advanced diagnostics in Norway
Presenter: Hege Russnes
Session: Poster session 01
214P - PESSA: A shiny app for pathway enrichment score-based survival analysis in cancer
Presenter: Ying Shi
Session: Poster session 01
215P - Identifying predictors of overall survival among TMB-low cancer patients treated with immune checkpoint inhibitors
Presenter: Camila Xavier
Session: Poster session 01
216P - PTCH1 mutation as a potential predictor of immune checkpoint inhibitors in gastrointestinal cancer
Presenter: Yang Tang
Session: Poster session 01